In a previous study, the fecal biomarkers calprotectin and α1-antitrypsin (α1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers calprotectin and α1-AT throughout the course of GvHD. Patients who were refractory to steroids had initially higher biomarker levels and in the course of GvHD demonstrated a continuous increase in fecal biomarkers. In contrast, the dynamics of calprotectin and α1-AT demonstrated low and decreasing levels in cortico-sensitive GvHD. In steroid-refractory patients who received a second line of treatment, the biomarker levels at the beginning of second-line treatment did not predict the subsequent response. Nevertheless, calprotectin levels progressively decreased in subsequent responders, whereas non-responders demonstrated continuously high levels of calprotectin. α1-AT values correlated to a lesser extent with the response to second-line treatment and remained elevated in both non-responders and responders. In conclusion, calprotectin monitoring can be of use in the management of immunosuppressive treatment in GI-GvHD.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation is performed with the intent of curing an array of hematologic pathologies. This attempt fails in a considerable number of patients because of treatment complications. In particular GvHD, a complex immune response of donor T cells recognizing minor genetic disparities in the recipient, will manifest in around 50% of allogeneic hematopoietic stem cell transplantation recipients, accounting for high mortality and morbidity. 1 First-line therapy consists of glucocorticoids, to which 40-70% of patients respond. 2 The failure to respond to first-line GvHD treatment is associated with very poor survival, 3 and there is no clearly established second-line treatment for corticosteroid-refractory (CS-refractory) GvHD. If the state of the patient allows, a second-line therapy may be attempted, usually by modifying the level of immunosuppression-for example, raising the dose of steroids, adding a further immunosuppressant, a mono or polyclonal Ab, or through other interventions such as mesenchymal stem cell administration or extracorporeal photophoresis. 4, 5 Although remission may then be achieved, it is often at the price of severe infectious complications, ultimately resulting in an unimproved long-term survival. 6 Several individual disease biomarkers such as serum albumin, thrombomodulin, angiopoietin-2 and vascular endothelial growth factor, as well as biomarker panels, have been studied in the setting of GvHD. [7] [8] [9] [10] Calprotectin is a protein of the S100 family, a group of proteins involved in regulating cell development, scaffolding, calcium metabolism and, in the case of calprotectin, also in antimicrobial functions and apoptosis induction upon neutrophil activation. 11, 12 Calprotectin measurement in the stool has been used to distinguish inflammatory bowel disorders (IBD) from functional gastrointestinal disorders, in order to monitor IBD therapy, and to predict clinical relapse of IBD.
13 α1-AT, a serine protease inhibitor of proinflammatory mediators, is considered to be a marker of protein-losing enteropathies. 14 In the context of gastrointestinal GvHD (GI-GvHD), calprotectin and α1-AT levels were found to be elevated and to predict the response to corticosteroids. [15] [16] [17] Although fecal testing is noninvasive and easily available, sensitivity and specificity are too low to replace conventional diagnostic tools-that is, histology.
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Acute GvHD can manifest in the skin, the liver and the gut, either sequentially, simultaneously in the skin and gut, or in a single organ such as the skin, but all as the result of a systemic process. Consensus treatment-response terminology in GvHD is traditionally based on the evolution of clinical symptoms, quantified as GvHD grading at defined time points. 19 Manifest symptoms at a precise moment in time do not necessarily reflect the general activity and severity of GvHD; that is, unforeseen relapse can rapidly ensue clinical remission. We therefore examined the dynamics of fecal calprotectin and α1-AT from the time of diagnosis of GvHD (GI and isolated skin) and further on as correlative biomarkers in first-and second-line treatment monitoring.
MATERIALS AND METHODS
The local ethical committee of the Hôpital Saint-Louis in Paris approved this prospective noninterventional study, which gathered patients from two noninterventional consecutive studies collecting stool samples with the aim of testing diagnostic and prognostic markers ('2009/30 NI study and 2014/43NICB'). All patients gave their consent to their participation in this study and to the evaluation of the data. Acute GvHD was suspected at the appearance of the following symptoms after transplantation: erythema/exanthema, diarrhea, nausea, emesis, abdominal pain, anorexia or cholestatic hepatitis. In the absence of contraindications such as the suspicion of ileus/intestinal perforation or patient dissent, endoscopy and histologic examinations were carried out. Acute GvHD was diagnosed and 1 graded along the lines of the Glucksberg and Consensus Criteria. 20, 21 Firstline treatment with corticosteroids at a dose of 1-2 mg/kg/d was initiated in all patients with acute GvHD grade 2 or higher. CS-refractory GvHD was defined either as progression at day 3, stable disease on day 7, or the absence of remission 2 weeks after the start of corticosteroids. Response to a second-line treatment was defined as the disappearance of symptoms according to the grading (score = 0) at any date. All patients who had received a second-line therapy with active GvHD who died after the treatment were considered as non-responders.
As described in detail in our previous study, 15 stool samples were gathered in plastic containers and dispatched to the laboratory within 48 h. Fecal α1-AT measurement was determined immediately using immunonephelometry on the BN ProSpec system (Siemens SAS, Saint-Denis, France) and reported per gram dry weight of stools. The measurement range was between 0.01 and 20 mg/g dry weight, and the upper normal limit was set at 1.5 mg/g dry weight. Fecal aliquots were frozen at − 80°C in order to quantify calprotectin using a 'sandwich'-type ELISA using polyclonal Ab (Calprest, Eurospital SPA, Trieste, Italy). The measurement range was 15-5000 μg/g, and 50 μg/g stool was set as the upper normal limit; results for calprotectin are provided as μg/g of stool wet weight. Mucosal inflammation is known to induce a significant increase in calprotectin, as observed in IBD. An expected, bias due to diarrhea volume is mitigated by the large reference range for calprotectin and by the quantification per gram of dry stool weight for α1-AT. Standard coprology exams (bacteriology including Clostridium difficile toxin detection, parasitology, viral PCR for CMV, norovirus, rotavirus and adenovirus) were routinely conducted for diarrhea.
Variables were compiled and compared using tests for categorical or continuous data where appropriate. All comparisons were two-sided, and P-values o 0.05 were considered significant. Statistical analyses were performed using SPSS version 19 (SPSS Inc, Chicago, IL, USA) and GRAPHPAD PRISM version 5.0a (GraphPad Software, San Diego, CA, USA). Patient and transplant characteristics are compiled in Table 1 .
RESULTS
Calprotectin and α1-AT concentrations at the diagnosis of GvHD Of 95 patients with repeat fecal biomarker measurements, 54 patients were diagnosed with GI-GvHD (63.5%) and seven were diagnosed with isolated skin GvHD (8.2%). Ten patients had infectious diarrhea at sampling, but did not develop GI-GvHD (Clostridium difficile-associated disease in five, CMV enteritis in four and one rotavirus infection). Patients with infectious diarrhea demonstrated slightly higher median calprotectin values (54 μg/g of stool, interquartile range (IQR): 26.3-90) compared with controls (40 μg/g of stool, IQR: 23-57.5) and patients with isolated skin GvHD (38 μg/g of stool, IQR: 35.5-56). The difference was nonsignificant (Kruskall-Wallis, P = 0.53), whereas significantly higher levels were found in patients at the time of diagnosis of GI-GvHD (318 μg/g of stool; IQR: 36-596, P = 0.003, compared with patients who did not have diarrhea) (Figure 1a ). Median α1-AT levels were in increasing order: in patients with isolated skin GvHD (0.43 mg/g dry weight, IQR: 0.23-3.45), in controls (0.51 mg/g dry weight, IQR: 0.34-0.76) and in hematopoietic stem cell transplantation recipients with infectious diarrhea (0.56 mg/g dry weight, IQR: 0.30-2.28) (Kruskall-Wallis, P = 0.94). Significantly higher levels Figure 2d) . The difference between calprotectin in cortico-responsiveness and resistance was significant at all times (onset P = 0.028, week 1 P = 0.038, week 2 P = 0.001), as it was for α1-AT (onset P = 0.008, week 1 P = 0.001, week 2 P o0.001). In non-responders, median calprotectin was 396.5 μg/g (IQR: 222-1077) at weeks 1-2, 1131.5 μg/g (IQR: 329-2162) at weeks 3-4 and 1529.5 μg/g (IQR: 775-2517) at weeks 5-6. Median α1-AT levels were 14.19 mg/g DW (IQR: 10.82-16.28) at weeks 1-2, 14.14 mg/g DW (IQR: 12.07-16.77) at weeks 3-4 and 9.80 mg/g DW (IQR: 7.69-11.86) at weeks 5-6. As of week 3 the difference in calprotectin levels according to response was significant (weeks 1-2 P = 0.89, weeks 3-4 P = 0.023, weeks 5-6 P = 0.005, Figure 3a and b). This trend could not be seen with α1-AT (weeks 1-2 P = 0.39, weeks 3-4 P = 0.89, weeks 5-6 P = 0.41, Figure 3c and d) , which was higher than the upper limit in almost all patients at all stages.
The patients who responded to a second-line therapy had protracted clinical response with long-lasting diarrhea. Figures 4  and 5 illustrate the clinical and fecal marker dynamics in secondline responders (4a-c) and non-responders (5a-c). One can observe that, although diarrhea persists in all patients, some finally respond and are alive several months after their first symptoms and without chronic diarrhea (Figure 4a-c) . The Fecal biomarkers in GvHDnon-responders in Figure 5 had increasing markers and died from GI-GvHD (one sepsis and two occlusions), whereas the responders had decreasing calprotectin levels. It should also be noted that neither in responders nor in non-responders do α1-AT levels normalize, which can be explained by the persistence of epithelial damage even after cessation of the inflammatory process.
DISCUSSION
In a previous study, high calprotectin and α1-AT levels at GI-GvHD onset were found to be predictive of subsequent steroid-resistant GvHD. 15 Here, we studied the dynamics of calprotectin and α1-AT from GI-GvHD onset to last symptoms for a correlation between marker evolution and GI-GvHD symptoms.
As found in our previous study, we can confirm that high calprotectin and α1-AT levels at the onset of GI-GvHD correlate with CS-refractory GvHD in this independent set of patients. The dynamics of fecal markers demonstrated continuously low levels in responders, although patients with CS-refractory GvHD had consistently high levels of calprotectin and α1-AT. When focusing on patients with persistent diarrhea in the context of CS-refractory GvHD, two patient profiles can be distinguished: long-term survivors who finally responded to second-line treatment and those who never responded. The long-term survivors had a progressive decrease in calprotectin levels (even when diarrhea persisted though the first weeks of treatment), whereas non-responders continued to demonstrate high levels. Further, sequential calprotectin measurements provided the advantage of avoiding the bias of interpretation because of interindividual variability. Although patients with CS-sensitive GvHD had a progressive decrease in α1-AT levels, patients with CS-refractory GvHD had very high levels that did not vary substantially with the subsequent response to a second-line therapy. One possible explanation might be that the step of complete mucosal reconstitution enabling patent protein retention and thus normalization of α1-AT loss after a long-standing and severe injury such as advanced GI-GvHD will lag behind the cessation of inflammation and resolution of diarrhea. 22 In practice, this aspect can be used in the context of patients with chronic GvHD who develop diarrhea but in whom sequential normal α1-AT and/or calprotectin levels should prompt further investigations of other causes of diarrhea.
Definitive conclusions are limited foremost by the heterogeneity of second-line therapies administered in this group and by the small sample size. Fecal biomarker follow-up does not seem useful in the management of patients who have a clear response to CS. As the treatment of patients with persistent diarrhea in GI-GvHD is particularly difficult and because the quantity of stools is not always available for precise GI-GvHD staging, sequential calprotectin levels can be used as indicators of response in more complex cases. There are few clinical or biological markers that can help in medical decision-making at this stage of the disease, as the majority have been tested at diagnosis but not during the evolution of disease. In conclusion, the fecal biomarker and particularly calprotectin levels can be used as noninvasive markers of response to first-and second-line treatment, the dynamics of calprotectin being a predictor of the later response. In patients with increasing levels, a new immunosuppressive therapy should be considered, whereas those with decreasing levels will probably benefit from immunosuppressive therapy tapering.
